Inhibrx Biosciences, Inc. (INBX) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 La Jolla, CA, 美国. 现任CEO为 Mark Paul Lappe.
INBX 拥有 IPO日期为 2024-06-04, 156 名全职员工, 在 NASDAQ Global Market, 市值为 $1.22B.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
